CENCORA INC (COR)

US03073E1055 - Common Stock

245.02  -0.67 (-0.27%)

After market: 246.71 +1.69 (+0.69%)

News Image
14 hours ago - Chartmill

Stay updated with the S&P500 stocks that are on the move in today's pre-market session.

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.

News Image
9 days ago - Investor's Business Daily

McKesson Stock Gets A RS Rating Lift To 75

The Relative Strength (RS) Rating for McKesson stock jumped into a new percentile Wednesday, as it got a lift from 70 to 75.

News Image
14 days ago - Investor's Business Daily

Cardinal Health Stock Sees IBD RS Rating Improve To 71

In a welcome move, Cardinal Health stock saw its Relative Strength (RS) Rating rise from 65 to 71 on Friday.

News Image
2 months ago - Market News Video

May 2025 Options Now Available For Cencora (COR)

News Image
2 months ago - Market News Video

Tuesday Sector Laggards: Healthcare, Utilities

News Image
3 months ago - The Motley Fool

Why Walgreens Boots Alliance Fell Another 22% in August

The retail pharmacy giant faces ever-mounting headwinds.

News Image
3 months ago - The Motley Fool

Is the Temu Hype Warranted?

School's in and we've also got a look at the challenges teachers face while saving for retirement.

News Image
3 months ago - Yahoo Finance

Drug distributors strike $300 million opioid settlement with US health plans

(Reuters) -The three largest U.S. drug distributors have agreed to pay $300 million to resolve claims by health insurers and benefit plans that they helped fuel the deadly U.S. opioid epidemic, according to court papers filed on Friday. The proposed class action settlement with McKesson Corp, Cencora Inc and Cardinal Health Inc was disclosed in a filing in federal court in Cleveland, Ohio, and requires a judge's approval. Paul Geller, a lawyer for the plaintiffs, said in a statement that Friday's deal covered third-party payers like union funds that "largely paid for the overprescribed and overmarketed pills and for the treatment required when their plan beneficiaries inevitably suffered opioid use disorder."

News Image
3 months ago - The Motley Fool

Is Cash Flow a Problem for Walgreens Boots Alliance?

There are plenty of red flags surrounding the business.

News Image
4 months ago - Investor's Business Daily

Health Care Giant McKesson Dives Amid Big Revenue Miss

McKesson earnings beat estimates, but the drug and health supplies distribution giant badly missed sales estimates. MCK stock dived.

News Image
4 months ago - Market News Video

Cencora Takes Over #195 Spot From Hess

News Image
4 months ago - InvestorPlace

COR Stock Earnings: Cencora Beats EPS, Beats Revenue for Q3 2024

COR stock results show that Cencora beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024.